Pharmacokinetic Comparison of Favipiravir Oral Solution and Tablet Formulations in Healthy Thai Volunteers

Article Virology

被撤回的出版物: Efficacy of favipiravir in COVID-19 treatment: a multi-center randomized study (Retracted article. See vol. 167, pg. 277, 2022)

Hany M. Dabbous et al.

Summary: Favipiravir shows promising efficacy in the treatment of COVID-19, reducing hospital stay and the need for mechanical ventilation.

ARCHIVES OF VIROLOGY (2021)

添加到收藏夹

Review Infectious Diseases

Role of favipiravir in the treatment of COVID-19

Shashank Joshi et al.

Summary: Favipiravir has shown promising results in clinical studies worldwide, demonstrating potential efficacy against COVID-19, and is being included in treatment protocols by multiple countries.

INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES (2021)

添加到收藏夹

Review Pharmacology & Pharmacy

Recommendations for Dosing of Repurposed COVID-19 Medications in Patients with Renal and Hepatic Impairment

Fiona Marra et al.

Summary: This paper reviewed the pharmacokinetics and available study data of experimental COVID-19 therapies in patients with renal or hepatic impairment to provide dosing recommendations. Recommendations were made based on available data, pharmacokinetic properties, dosing, treatment duration, and known toxicities.

DRUGS IN R&D (2021)

添加到收藏夹

Article Pharmacology & Pharmacy

Interactions of Potential Anti-COVID-19 Compounds with Multispecific ABC and OATP Drug Transporters

Agnes Telbisz et al.

Summary: This study examined the interactions of repurposed drugs with key human multidrug transporters, showing numerous pharmacologically relevant transporter interactions that may raise concerns about potential toxicities of these drugs in clinical settings.

PHARMACEUTICS (2021)

添加到收藏夹

Article Biochemical Research Methods

A novel, rapid and simple UPLC-MS/MS method for quantification of favipiravir in human plasma: Application to a bioequivalence study

Mamdouh R. Rezk et al.

Summary: A novel UPLC-MS/MS method using lamivudine as an internal standard was developed and validated for determination of favipiravir in human plasma. The method was simple, rapid, and highly accurate, with a low quantification limit allowing its application in bioequivalence studies in healthy volunteers.

BIOMEDICAL CHROMATOGRAPHY (2021)

添加到收藏夹

Article Chemistry, Analytical

A novel LC-MS/MS method for determination of the potential antiviral candidate favipiravir for the emergency treatment of SARS-CoV-2 virus in human plasma: Application to a bioequivalence study in Egyptian human volunteers

Mosaad Morsy et al.

Summary: A novel LC-MS/MS method was developed and validated for the bioanalysis of favipiravir in human plasma, demonstrating bioequivalence of a new formulation of favipiravir compared to the reference product in healthy Egyptian volunteers.

JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS (2021)

添加到收藏夹

Review Infectious Diseases

Favipiravir for the treatment of patients with COVID-19: a systematic review and meta-analysis

Toshie Manabe et al.

Summary: The study suggests that favipiravir shows promising efficacy in treating patients with COVID-19, inducing viral clearance within 7 days and contributing to clinical improvement within 14 days. The drug is especially effective for patients with mild-to-moderate illness. However, additional well-designed studies are needed to determine the optimal dosage and duration of treatment.

BMC INFECTIOUS DISEASES (2021)

添加到收藏夹

Review Infectious Diseases

Mortality-related risk factors of COVID-19: a systematic review and meta-analysis of 42 studies and 423,117 patients

Zelalem G. Dessie et al.

Summary: Chronic comorbidities, complications, and demographic factors such as acute kidney injury, COPD, diabetes, hypertension, CVD, cancer, increased D-dimer, male gender, older age, current smoker, and obesity are identified as clinical risk factors for fatal outcomes related to coronavirus mortality, according to large dataset from 42 studies involving 423,117 patients. The findings provide valuable insights for future research, control, and prevention of the disease.

BMC INFECTIOUS DISEASES (2021)

添加到收藏夹

Article Pediatrics

Favipiravir use in children with COVID-19 and acute kidney injury: is it safe?

Yasemin Ozsurekci et al.

Summary: This study aimed to share the experience of using favipiravir in pediatric patients with COVID-19 and kidney impairment. Results showed that favipiravir may be a suitable therapeutic option for COVID-19 patients with kidney injury without needing dose adjustment.

PEDIATRIC NEPHROLOGY (2021)

添加到收藏夹

Review Multidisciplinary Sciences

The efficacy and safety of Favipiravir in treatment of COVID-19: a systematic review and meta-analysis of clinical trials

Soheil Hassanipour et al.

Summary: The meta-analysis of Favipiravir in the treatment of COVID-19 showed significant clinical improvement in the Favipiravir group compared to the control group after seven days of hospitalization. However, there was no significant difference in viral clearance and oxygen therapy requirement between the two groups. The mortality rate was approximately 30% lower in the Favipiravir group, but this finding was not statistically significant.

SCIENTIFIC REPORTS (2021)

添加到收藏夹

Review Pharmacology & Pharmacy